TKNO
Neutral signalScored 2026-10-06 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Alpha Teknova, Inc.
- Nom
- Alpha Teknova, Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NASDAQ
- Capitalisation
- $330.2M
- Employés
- 158
- PDG
- Stephen Gunstream
- Site web
- https://www.teknova.com
- Marché
- AZTABLFSHBIOLABMLABMRVI
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-10 | Richard Blumenthal | Buy | $1,001 - $15,000 | Filing |
Signal
Neutral signalScored 2026-10-06 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
TKNO presents a meaningful near-term catalyst with the FDA Type II Drug Master File filing and a Zacks Buy upgrade supporting positive momentum, but the underlying fundamentals remain deeply concerning with persistent…
The first sentence of the analysis written for TKNO on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.58 · operating margin -42% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 33.2% | 19.2% | 28.1% | 42.2% | 47.8% | |
| Ebit Margin | -40.7% | -69.3% | -85.0% | -69.7% | -32.7% | |
| Ebitda Margin | -25.0% | -51.8% | -69.6% | -62.0% | -24.8% | |
| Operating Profit Margin | -41.9% | -69.3% | -96.9% | -119.9% | -32.5% | |
| Pretax Profit Margin | -42.5% | -71.1% | -101.1% | -119.2% | -34.3% | |
| Continuous Operations Profit Margin | -42.6% | -70.9% | -100.3% | -114.6% | -26.6% | |
| Net Profit Margin | -42.6% | -70.9% | -100.3% | -114.6% | -26.6% | |
| Bottom Line Profit Margin | -42.6% | -70.9% | -100.3% | -114.6% | -26.6% | |
| Current Ratio | 4.579 | 3.816 | 5.145 | 5.622 | 13.070 | |
| Quick Ratio | 3.643 | 3.209 | 3.838 | 4.496 | 12.374 | |
| Solvency Ratio | -0.314 | -0.554 | -0.807 | -0.846 | -0.297 | |
| Cash Ratio | 0.784 | 0.331 | 3.209 | 3.884 | 11.303 | |
| Price To Earnings Ratio | -11.875 | -14.649 | -3.216 | -3.337 | -58.514 | |
| Price To Earnings Growth Ratio | 0.271 | 0.288 | 0.103 | -0.009 | 0.184 | |
| Forward Price To Earnings Growth Ratio | 0.271 | 0.288 | 0.103 | -0.009 | 0.184 | |
| Price To Earnings Diluted Ratio | -11.875 | -14.649 | -3.216 | -3.337 | -58.514 | |
| Price To Earnings Diluted Growth Ratio | 0.271 | 0.288 | 0.103 | -0.009 | 0.184 | |
| Price To Book Ratio | 2.955 | 4.737 | 1.318 | 1.586 | 4.006 | |
| Price To Sales Ratio | 5.016 | 10.341 | 3.235 | 3.824 | 15.550 | |
| Price To Free Cash Flow Ratio | -20.751 | -28.879 | -4.437 | -2.851 | -19.819 | |
| Price To Operating Cash Flow Ratio | -23.506 | -31.501 | -6.309 | -5.781 | -63.258 | |
| Debt To Assets Ratio | 0.146 | 0.254 | 0.237 | 0.278 | 0.071 | |
| Debt To Equity Ratio | 0.220 | 0.366 | 0.338 | 0.424 | 0.083 | |
| Debt To Capital Ratio | 0.180 | 0.268 | 0.253 | 0.298 | 0.077 | |
| Long Term Debt To Capital Ratio | 0.162 | 0.103 | 0.128 | 0.180 | 0.077 | |
| Financial Leverage Ratio | 1.506 | 1.441 | 1.428 | 1.524 | 1.163 | |
| Working Capital Turnover Ratio | 1.384 | 1.104 | 0.843 | 0.576 | 0.697 | |
| Operating Cash Flow Ratio | -1.147 | -1.105 | -2.120 | -2.520 | -1.171 | |
| Operating Cash Flow Sales Ratio | -0.213 | -0.328 | -0.513 | -0.662 | -0.246 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.133 | 1.091 | 1.422 | 2.027 | 3.192 | |
| Debt Service Coverage Ratio | -3.947 | -4.117 | -30.301 | 0.000 | -10.749 | |
| Interest Coverage Ratio | -23.910 | -38.058 | -42.693 | 0.000 | -20.387 | |
| Short Term Operating Cash Flow Coverage Ratio | -4.609 | -3.063 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.571 | -0.411 | -0.618 | -0.648 | -0.764 | |
| Capital Expenditure Coverage Ratio | -7.531 | -11.014 | -2.371 | -0.973 | -0.456 | |
| Dividend Paid And Capex Coverage Ratio | -7.531 | -11.014 | -2.371 | -0.973 | -0.456 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -20.935 | -21.300 | -4.725 | -6.168 | -54.341 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 33.2% | ▲14.0% | ▼-0.9% |
| Ebit Margin | -40.7% | ▲28.6% | ▲18.8% |
| Ebitda Margin | -25.1% | ▲26.8% | ▲21.6% |
| Operating Profit Margin | -41.9% | ▲27.4% | ▲30.2% |
| Pretax Profit Margin | -42.4% | ▲28.6% | ▲31.2% |
| Continuous Operations Profit Margin | -42.6% | ▲28.3% | ▲28.4% |
| Net Profit Margin | -42.6% | ▲28.3% | ▲28.4% |
| Bottom Line Profit Margin | -42.6% | ▲28.3% | ▲28.4% |
| Current Ratio | 4.579 | ▲0.763 | ▼-1.867 |
| Quick Ratio | 3.643 | ▲0.434 | ▼-1.869 |
| Solvency Ratio | -0.314 | ▲0.241 | ▲0.250 |
| Cash Ratio | 0.784 | ▲0.454 | ▼-3.118 |
| Price To Earnings Ratio | -11.875 | ▲2.774 | ▲6.443 |
| Price To Earnings Growth Ratio | 0.271 | ▼-0.017 | ▲0.103 |
| Forward Price To Earnings Growth Ratio | 0.271 | ▼-0.017 | ▲0.103 |
| Price To Earnings Diluted Ratio | -11.875 | ▲2.774 | ▲6.443 |
| Price To Earnings Diluted Growth Ratio | 0.271 | ▼-0.017 | ▲0.103 |
| Price To Book Ratio | 2.955 | ▼-1.782 | ▲0.035 |
| Price To Sales Ratio | 5.016 | ▼-5.325 | ▼-2.578 |
| Price To Free Cash Flow Ratio | -20.751 | ▲8.128 | ▼-5.404 |
| Price To Operating Cash Flow Ratio | -23.506 | ▲7.995 | ▲2.565 |
| Debt To Assets Ratio | 0.146 | ▼-0.108 | ▼-0.051 |
| Debt To Equity Ratio | 0.220 | ▼-0.146 | ▼-0.066 |
| Debt To Capital Ratio | 0.180 | ▼-0.088 | ▼-0.035 |
| Long Term Debt To Capital Ratio | 0.162 | ▲0.059 | ▲0.032 |
| Financial Leverage Ratio | 1.506 | ▲0.065 | ▲0.093 |
| Working Capital Turnover Ratio | 1.384 | ▲0.280 | ▲0.463 |
| Operating Cash Flow Ratio | -1.147 | ▼-0.042 | ▲0.466 |
| Operating Cash Flow Sales Ratio | -0.213 | ▲0.115 | ▲0.179 |
| Free Cash Flow Operating Cash Flow Ratio | 1.133 | ▲0.042 | ▼-0.640 |
| Debt Service Coverage Ratio | -3.947 | ▲0.170 | ▲5.876 |
| Interest Coverage Ratio | -23.910 | ▲14.148 | ▲1.100 |
| Short Term Operating Cash Flow Coverage Ratio | -4.609 | ▼-1.546 | ▼-3.074 |
| Operating Cash Flow Coverage Ratio | -0.571 | ▼-0.160 | ▲0.031 |
| Capital Expenditure Coverage Ratio | -7.531 | ▲3.483 | ▼-3.062 |
| Dividend Paid And Capex Coverage Ratio | -7.531 | ▲3.483 | ▼-3.062 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -20.935 | ▲0.365 | ▲0.559 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $203.2M | $390.3M | $118.7M | $158.4M | $573.7M | |
| Enterprise value | $212.5M | $416.8M | $120.7M | $158.5M | $498.0M | |
| EV / Sales | 5.24x | 11.04x | 3.29x | 3.83x | 13.50x | |
| EV / Op. cash flow | -24.57x | -33.64x | -6.41x | -5.78x | -54.92x | |
| EV / Free cash flow | -21.69x | -30.84x | -4.51x | -2.85x | -17.21x | |
| EV / EBITDA | -20.93x | -21.30x | -4.72x | -6.17x | -54.34x | |
| Net debt / EBITDA | -0.91x | -1.35x | -0.08x | -0.00x | 8.25x | |
| Current ratio | 4.58x | 3.82x | 5.14x | 5.62x | 13.07x | |
| Income quality | 0.50x | 0.46x | 0.51x | 0.58x | 0.93x | |
| Graham net-net | -$0 | $0 | -$0 | -$0 | $3 | |
| Tax burden | 100.3% | 99.7% | 99.2% | 96.1% | 77.6% | |
| Interest burden | 104.3% | 102.6% | 118.8% | 171.2% | 104.9% | |
| Working capital | $27.0M | $31.6M | $36.8M | $50.3M | $93.5M | |
| Invested capital | $94.8M | $106.2M | $117.9M | $139.1M | $158.6M | |
| Return on assets | -16.7% | -22.5% | -28.6% | -31.2% | -5.9% | |
| Operating ROA | -15.3% | -21.1% | -25.3% | -31.2% | -10.5% | |
| Return on tangible assets | -18.8% | -25.3% | -32.2% | -35.2% | -7.5% | |
| Return on equity | -25.1% | -32.5% | -40.9% | -47.5% | -6.8% | |
| Return on invested capital | -17.3% | -23.0% | -29.0% | -33.2% | -5.9% | |
| Return on capital employed | -17.7% | -24.3% | -29.7% | -35.1% | -7.6% | |
| Earnings yield | -8.5% | -6.9% | -31.0% | -30.0% | -1.7% | |
| Free cash flow yield | -4.8% | -3.5% | -22.5% | -35.1% | -5.0% | |
| Capex / Op. cash flow | -13.3% | -9.1% | -42.2% | -102.7% | -219.2% | |
| Capex / Depreciation | 18.1% | 17.1% | 140.2% | 889.4% | 689.5% | |
| Capex / Sales | 2.8% | 3.0% | 21.6% | 68.0% | 53.9% | |
| SG&A / Sales | 66.8% | 78.1% | 94.8% | 90.4% | 65.5% | |
| R&D / Sales | 5.4% | 7.3% | 15.2% | 18.7% | 11.7% | |
| Stock comp / Sales | 8.5% | 9.7% | 11.3% | 9.0% | 4.2% | |
| Intangibles / Total assets | 11.5% | 11.0% | 11.1% | 11.5% | 21.2% | |
| Days sales outstanding | 42d | 42d | 39d | 38d | 58d | |
| Days payables outstanding | 19d | 10d | 21d | 37d | 43d | |
| Operating cycle | 137d | 123d | 200d | 224d | 160d | |
| Cash conversion cycle | 118d | 113d | 179d | 187d | 118d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-04 Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze What happened Alpha Teknova, Inc. (NASDAQ: TKNO) is making it easier for cell-therapy developers to use PluriFreeze without rebuilding the same regulatory package from scratch. Pluristyx is completing a Type II Drug Master File for the cryopreservation system. Authorized customers can cross-reference the confidential chemistry, manufacturing and controls information in Investigational New Drug and Biologics
- 2026-10-02 Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System Teknova and Pluristyx announce a Type II FDA Drug Master File for the PluriFreeze™ cryopreservation system, now available to developers for cross-reference
- 2026-10-01 All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-09-30 Head-To-Head Survey: Alpha Teknova (NASDAQ:TKNO) and Icon (NASDAQ:ICLR) Icon (NASDAQ: ICLR - Get Free Report) and Alpha Teknova (NASDAQ: TKNO - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends. Profitability This table compares Icon and Alpha Teknova''s net
- 2026-09-25 88,412 Alpha Teknova, Inc. $TKNO Shares Sold by Squarepoint Ops LLC Squarepoint Ops LLC reduced its stake in shares of Alpha Teknova, Inc. (NASDAQ: TKNO) by 71.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,948 shares of the company''s stock after selling 88,412 shares during the quarter. Squarepoint
- 2026-09-22 Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last? Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-09-16 Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling Teknova''s Fill-Tek™ Dispensing System fills single-use bag orders across multiple sizes and quantities as a single lot, with no added turnaround time.
- 2026-08-19 Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.
- 2026-08-19 Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy? Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-10 Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here''s is How to Trade The mean of analysts'' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.